Literature DB >> 9012761

Giant cell arteritis and polymyalgia rheumatica.

G G Hunder1.   

Abstract

Giant cell arteritis and polymyalgia rheumatica are linked conditions that frequently occur in the same patient. They are more common in northern Europe and persons of European descent than in other populations. Recent investigations have begun to provide information about the pathogenesis of both syndromes. Both respond to corticosteroids but at different dose levels. Although a number of vascular complications may occur, the outlook is excellent.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9012761     DOI: 10.1016/s0025-7125(05)70511-3

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  12 in total

1.  Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells.

Authors:  M Kaiser; B Younge; J Björnsson; J J Goronzy; C M Weyand
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

Review 2.  Polymyalgia rheumatica/temporal arteritis: recent advances.

Authors:  Maria-Louise Barilla-LaBarca; Deborah J Lenschow; Richard D Brasington
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

Review 3.  Rheumatology: 11. Evaluation of the patient with pain all over.

Authors:  M P Puttick
Journal:  CMAJ       Date:  2001-01-23       Impact factor: 8.262

4.  A case of giant cell arteritis with massive pericardial effusion.

Authors:  Yuya Matsue; Masakazu Ohno; Wataru Nagahori; Makoto Suzuki; Akihiko Matsumura; Yuji Hashimoto
Journal:  Heart Vessels       Date:  2011-02-03       Impact factor: 2.037

5.  An immunohistochemical analysis of folate receptor beta expression and distribution in giant cell arteritis - a pilot study.

Authors:  Shirley Albano-Aluquin; Jozef Malysz; Vincent R Aluquin; Manohar Ratnam; Nancy Olsen
Journal:  Am J Clin Exp Immunol       Date:  2017-12-20

6.  Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis.

Authors:  H L Rittner; V Hafner; P A Klimiuk; L I Szweda; J J Goronzy; C M Weyand
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

7.  Increased 67gallium uptake among polymyalgia rheumatica patients. Is it additional evidence of its vasculitic nature?

Authors:  T Reitblat; C L Ben-Horin; A Reitblat
Journal:  Rheumatol Int       Date:  2006-04-05       Impact factor: 2.631

Review 8.  Spectrum of giant cell vasculitis.

Authors:  N Mohan; G Kerr
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

9.  Glucocorticoid usage in giant cell arteritis over six decades (1950 to 2009).

Authors:  A Chandran; Pr D Udayakumar; T A Kermani; K J Warrington; C S Crowson; E L Matteson
Journal:  Clin Exp Rheumatol       Date:  2015-05-26       Impact factor: 4.473

Review 10.  [Temporal arteritis (giant cell arteritis). Clinical picture, histology, and treatment].

Authors:  T Ness; C Auw-Hädrich; D Schmidt
Journal:  Ophthalmologe       Date:  2006-04       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.